XERS peer analysis
Xeris Biopharma (XERS) against its competitors: price, today's move, 1-year return and market value side by side.
XERS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ASND Ascendis Pharma | $248.82 | -0.98% | 22.14% | $16.53B |
| CORT Corcept Therapeutics | $80.39 | -0.89% | 11.26% | $8.77B |
| ETON Eton Pharmaceuticals | $50.81 | -2.63% | 178.41% | $1.49B |
| GHRS GH Research | $20.86 | -2.98% | 66.35% | – |
| MBX MBX Biosciences | $54.34 | -2.74% | 149.38% | – |
| MNKD MannKind | $3.66 | 4.43% | -34.14% | $1.13B |
| SEPN Septerna | $43.32 | -1.55% | 101.58% | – |
| SPRB Spruce Biosciences | $46.39 | -0.92% | -56.75% | – |
| XERS Xeris Biopharma | $10.13 | -5.42% | 4.33% | $1.95B |
- XERS's peers: ASND (Ascendis Pharma), CORT (Corcept Therapeutics), ETON (Eton Pharmaceuticals), GHRS (GH Research), MBX (MBX Biosciences), MNKD (MannKind), SEPN (Septerna), SPRB (Spruce Biosciences).
Updated 2026-11-02 23:14 UTC